drugset / Trial / NCT01487460

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients

NCT01487460 ↗

Phase 1 Completed 137 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindOther

Summary

This study will assess the safety, tolerability, and effect of TAP311 on blood lipids in healthy subjects and in patients who have dyslipidemia. The effect of food on TAP311 concentration in blood and effect of TAP311 administration on simvastatin concentration will also be assessed in healthy volunteers.

Timeline

Start
2011-11
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject TAP311 Unknown — —

Indications